Hematopoiesis News Volume 6.28 | Jul 21 2015

    0
    27

    Newsletter Issue

    Hematopoiesis News 6.29 July 21, 2015

    Hematopoiesis News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  HN on Twitter

     
    TOP STORY
    The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential
    Investigators report that leukemia stem cells (LSCs) in MLL-associated leukemia reside in an epigenetic state of relative genome-wide high-level H3K4me3 and low-level H3K79me2. LSC differentiation was associated with reversal of these broad epigenetic profiles, with concomitant downregulation of crucial MLL target genes and the LSC maintenance transcriptional program that was driven by the loss of H3K4me3, but not H3K79me2. [Cancer Cell] Abstract | Graphical Abstract

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells
    Researchers showed that Runx1-deficient hematopoietic stem and progenitor cells have a slow growth, low biosynthetic, small cell phenotype and markedly reduced ribosome biogenesis. [Cell Stem Cell]
    Abstract
    | Graphical Abstract

    Leukemic Marrow Infiltration Reveals a Novel Role for Egr3 as a Potent Inhibitor of Normal Hematopoietic Stem Cell Proliferation
    The authors used a robust non-irradiated mouse model of human MLL-AF9 leukemia to examine the suppression of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells during leukemia cell expansion in vivo. Gene expression profiling and further functional validation revealed that Egr3 was a strong limiting factor for the proliferative potential of HSCs. [Blood] Abstract

    Regulation of Hematopoiesis and Methionine Homeostasis by mTORC1 Inhibitor NPRL2
    Scientists showed that nitrogen permease regulator-like 2 (NPRL2) is required for mouse viability and that its absence significantly compromised fetal liver hematopoiesis in developing embryos. [Cell Rep]
    Full Article | Graphical Abstract

    Deficiency of the Ribosome Biogenesis Gene Sbds in Hematopoietic Stem and Progenitor Cells Causes Neutropenia in Mice by Attenuating Lineage Progression in Myelocytes
    Researchers established the first mammalian model of neutropenia in Shwachman-Diamond syndrome through targeted downregulation of Sbds in hematopoietic stem and progenitor cells expressing the myeloid transcription factor CCAAT/enhancer binding protein α. [Haematologica] Abstract | Full Article

    Autophagy Confers DNA Damage Repair Pathways to Protect the Hematopoietic System from Nuclear Radiation Injury
    Investigators observed that ex vivo autophagy activation reversed the proliferation inhibition, apoptosis, and DNA damage in irradiated hematopoietic cells. [Sci Rep] Full Article

    Frizzled-6 Regulates Hematopoietic Stem/Progenitor Cell Survival and Self-Renewal
    Scientists showed that a noncanonical Wnt receptor, Frizzled-6, regulates hematopoietic stem/progenitor cell expansion and survival in a hematopoietic cell-intrinsic manner. [J Immunol] Abstract

    The Drosophila Histone Demethylase dKDM5/LID Regulates Hematopoietic Development
    The authors report the essential contribution of dKDM5/LID to hematopoiesis in Drosophila. Their results showed that dKDM5/LID is abundant in hemocytes and that its depletion induces over-proliferation and differentiation defects of larval hemocytes and disrupts organization of the actin cytoskeleton. [Dev Biol] Abstract

    CLINICAL RESEARCH

    Stem Cell Transplantation in Severe Congenital Neutropenia: An Analysis from the European Society for Blood and Marrow Transplantation
    Investigators report on the outcome of 136 severe congenital neutropenia patients who underwent hematopoietic stem cell transplantation between 1990 and 2012 in European and Middle East centers. [Blood] Abstract

    Metabolic Syndrome in Adults Who Received Hematopoietic Stem Cell Transplantation for Acute Childhood Leukemia: An LEA Study
    Researchers evaluated prospectively the incidence and risk factors of the metabolic syndrome and its components in 170 adult patients who received an hematopoietic stem cell transplantation for childhood. [Bone Marrow Transplant] Abstract

    FLT3 Mutational Status Is an Independent Risk Factor for Adverse Outcomes after Allogeneic Transplantation in AML
    The authors investigated FMS-like tyrosine kinase-3 (FLT3) mutational status on transplant outcomes. They conducted a retrospective cohort study of 262 consecutive AML patients who underwent first-time allogeneic hematopoietic cell transplantation, of whom 171 had undergone FLT3-internal tandem duplication mutational testing. [Bone Marrow Transplant] Abstract

     
    REVIEWS
    Lost in Translation: Pluripotent Stem Cell-Derived Hematopoiesis
    While the generation of fully defined hematopoietic stem cells from pluripotent stem cells (PSCs) remains challenging in vitro, the authors underline the instructive role of cell extrinsic factors such as cytokines for the generation of PSC-derived mature hematopoietic cells. [EMBO Mol Med] Full Article

    BMSCs and Hematopoiesis
    The authors review key molecular pathways, adhesion molecules and ligand/receptor interactions that mediate the crosstalk between bone marrow mesenchymal stem cells (BMSCs) and hematopoietic stem cells in health and disease. [Immunol Lett] Abstract

    Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

     
    INDUSTRY NEWS
    Amgen Announces Positive BLINCYTO® (Blinatumomab) Phase II Study Results in Patients with Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
    Amgen announced the top-line results of a Phase II open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® in adults with relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. [Amgen] Press Release

    Medtown Ventures, LLC Announces Exclusive License Agreement with Georgia Tech Research Corporation
    Medtown Ventures, LLC announced that it has entered into an exclusive license agreement with Georgia Tech Research Corporation for a new adhesive-signature based stem cell selection and isolation technology. [Medtown Ventures, LLC] Press Release

    From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Cell Symposia Meeting – Stem Cell Epigenetics
    September 20-22, 2015
    Sitges, Spain

    Visit our events page to see a complete list of events in the hematopoiesis community.

     
    JOB OPPORTUNITIES
    NEW Research Associate – Cell Biology (Editas Medicine)

    NEW Postdoctoral Research Fellow – Hematopoietic Stem and Progenitor Cell Gene Therapy (Fred Hutchinson Cancer Research Center)

    Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    PhD Position – Drug Releasing, Nanostructured Biomaterials for Adult Stem Cells (Karlsruhe Institute of Technology)

    Postdoctoral Position – Splicing in Hematopoiesis (Northwestern University)

    Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

    Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

    Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

    Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Hematopoiesis News: Archives | Events | Contact Us